Hugh Y. Rienhoff, Jr. M.D.
Chief Executive Officer
Dr. Rienhoff is a San Francisco Bay area clinical scientist and entrepreneur. He was a founding director of Healtheon/WebMD (HLTH) and Aurora Biosciences (ABSC). In 1998 he founded DNA Sciences (originally Kiva Genetics) and served as its Chairman and CEO. Dr. Rienhoff founded and was Chief Executive Officer of FerroKin BioSciences from 2007 until its acquisition by Shire Pharmaceuticals in 2012. Dr. Rienhoff founded and is Chief Executive Officer of Imago BioSciences, a clinical stage company focused on hematologic diseases.
Dr. Rienhoff trained in mathematics, medicine, and genetics at Harvard University, Johns Hopkins University, and the Fred Hutchinson Cancer Research Center in Seattle, Washington. He received a Doctor of Medicine degree from Johns Hopkins University School of Medicine and a Bachelor of Arts degree in Biology and English Literature from Williams College.
Laura G. Eichorn
Chief Operating Officer
Ms. Eichorn is based in Central Illinois and works as Chief Operating Officer of Imago BioSciences, Inc. She brings to the team over 25 years of operational experience. Ms. Eichorn manages finance, legal, human resources, and marketing related activities. She also assists Dr. Rienhoff in business development opportunities for the Company. Ms. Eichorn is a founding employee of Imago.
Prior to working at Imago BioSciences, Ms. Eichorn was Vice President of Operations and Finance at FerroKin BioSciences, Inc. beginning as a founding employee in 2007 through the FerroKin acquisition in April 2012 by Shire Pharmaceuticals. FerroKin BioSciences developed a new treatment for transfusional iron overload, an orphan indication in the setting of rare hereditary and acquired anemias such as thalassemia major, sickle cell disease and myelodysplastic syndrome.
Ms. Eichorn began her career at New Enterprise Associates in Baltimore, MD in 1995. Ms. Eichorn, along with Hugh Rienhoff, went on to establish a US office for UK based Abingworth Venture Management in 1997. She then went to work at Fremont, CA based DNA Sciences followed by Bay Area based Vanguard Ventures and DataHooks, Inc.
Ms. Eichorn has a Bachelor of Arts Degree from Frostburg State University in International Studies with a concentration in Politics
Senior Vice President, Clinical Operations
Ms. Peppe is a Boston area clinical researcher with more than 25 years of experience. Ms. Peppe is currently working as Senior Vice President, Clinical Operations at Imago BioSciences, Inc., where she oversees all operational aspects of the global clinical development program. Ms. Peppe is a founding employee of Imago.
Ms. Peppe joined FerroKin BioSciences in 2010 as a Senior Director, and was Senior Vice President, Clinical Operations at the time of FerroKin’s acquisition by Shire Pharmaceuticals in 2012. FerroKin BioSciences was developing a new treatment for transfusional iron overload, an orphan indication in the setting of rare hereditary and acquired anemias such as thalassemia major, sickle cell disease and myelodysplastic syndrome.
Prior to joining FerroKin BioSciences, Ms. Peppe was an Associate Director at Genzyme Corporation, where she worked for 12 years. While in clinical development at Genzyme, she managed Phase 1 through Phase 3 trials in various indications including: hypercholesterolemia, psoriasis, clostridium difficile-associated diarrhea (CDAD), and relapsing-remitting multiple sclerosis (MS). Within the CDAD program, she was the Global Study Lead responsible for oversight of two identical Phase 3 trials which were initiated in 16 countries at ~300 sites, enrolling greater than 1100 patients. Within the MS program, her responsibilities included cross functional team leadership for a global Phase 2 trial, as well as oversight of an expansive Risk Management Program which involved production and maintenance of 16 patient/physician education materials in 14 languages, and interactive voice response system (IVRS)/web-based safety monitoring for all ongoing MS trials.
While in pharmacovigilance at Genzyme, Ms. Peppe was the operational lead responsible for oversight of two Lysosomal Storage Disorder (LSD) programs.
Ms. Peppe began her clinical research career as consortium lead study coordinator at the Dana-Farber Cancer Institute where she spent five years working on a Phase 4 pediatric acute lymphoblastic leukemia trial.
Ms. Peppe received a Bachelor of Arts degree in psychology from Smith College.
Amy E. Tapper, Ph.D.
Senior Vice President, Non-Clinical and CMC
Dr. Tapper is a Boston area scientist with almost 20 years of industry experience. Dr. Tapper is currently the Senior Vice President of Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical Development for Imago BioSciences. Dr. Tapper manages all aspects of CMC for both drug substance and drug product, as well as supports all non-clinical development activities. Dr. Tapper is a founding employee of Imago.
Dr. Tapper began her career at Genzyme Drug Discovery and Development as a Staff Scientist in chemical process development. At Genzyme, Dr. Tapper worked on several polymer and small molecule candidates. In 2004 she moved to Peptimmune as an Associate Director of CMC and technical program management. While at Peptimmune, she led the chemistry and development program for a Phase 1 anti-obesity candidate, and also managed the chemistry and manufacturing for several of their peptide therapies. In 2007 she moved to Momenta Pharmaceuticals as a Principal Scientist working on a novel anticoagulant compound for acute coronary syndrome in Phase 2 clinical trials.
Dr. Tapper joined Ferrokin BioSciences in 2007 as a founding employee and was Senior Vice President of CMC and Non-Clinical until its acquisition by Shire Pharmaceuticals in April 2012. FerroKin BioSciences was developing a new treatment for transfusional iron overload, an orphan indication in the setting of rare hereditary and acquired anemias such as thalassemia major, sickle cell disease and myelodysplastic syndrome.
Dr. Tapper received a Ph.D. in chemistry from Boston University and B.S. in chemistry from Boston College. She has been very active in the National American Chemical Society and also in the Northeastern Section of the American Chemical Society (NESACS). She was the chair of the NESACS in 2005.